AsclepiX Therapeutics: Private, ophthalmology focused early stage company; technology out of Johns Hopkins. Lead compound AXT107: novel peptide, inhibiting VEGF and activating Tie2 is the only therapeutic in clinical development for DME and wet AMD that was identified through a process of Artificial Intelligence, mining the human proteome for cryptic anti angiogenic and homeostatic peptides, rather than through a standard drug development process. AXT107 demonstrated efficacy and durability in rabbit and mouse models that is superior to standard of care Eylea. Planning mid 2020 IND submission and 3Q20 Ph1/2 initiation (DME and wetAMD).
Sector/Industry:
Healthcare/Biotechnology
Characteristics:
Based in...
US - South Atlantic
Clinical Stage
Pre-Clinical Stage
Disease Space
Ophthalmology
Listing
Private
Website:
Profiles:
Address:
301 West 29th Street
Suite 2004
Baltimore, MD 21211
United States

Company Participants at Boston Private Company Showcase

  • Wendy Perrow, MBA, CEO

Upcoming Company Event Participation

Fall Private Company Showcase 2020

VIRTUAL, October 15, 2020